Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2018 08:00 ET | Source: Celtaxsys, Inc.

Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference

ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
October 11, 2018 08:00 ET | Source: Celtaxsys, Inc.

Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference

ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...
August 02, 2018 08:00 ET | Source: Celtaxsys, Inc.

Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

-Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients --Celtaxsys,...
May 17, 2018 08:00 ET | Source: Celtaxsys, Inc.

Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
February 01, 2018 08:00 ET | Source: Celtaxsys, Inc.

Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

New patents build on previously granted composition of matter protection for acebilustat, with additional intellectual protection for use in cystic fibrosis, as well as new compositions for second...
January 04, 2018 08:00 ET | Source: Celtaxsys, Inc.

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

ATLANTA, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the...
May 17, 2017 08:00 ET | Source: Celtaxsys, Inc.

Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of novel anti-inflammatory investigational therapy, oral acebilustat, to preserve lung function in CF patients

ATLANTA, GA--(Marketwired - May 17, 2017) - Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare pulmonary diseases, announced...
January 09, 2017 08:02 ET | Source: Celtaxsys, Inc.

Celtaxsys Welcomes New Board Member Abel De La Rosa

ATLANTA, GA--(Marketwired - January 09, 2017) - Celtaxsys, a clinical stage pharmaceutical development company focused on advancing novel anti-inflammatory treatment for rare and orphan diseases,...
November 03, 2016 08:02 ET | Source: Celtaxsys, Inc.

Celtaxsys Announces Publication of Clinical Trial Results Demonstrating Its Novel Anti-inflammatory Medicine, Oral Acebilustat, Markedly Reduced Lung Inflammation Without Increased Risk of Immunosuppression, in Patients with Cystic Fibrosis (CF)

ATLANTA, GA--(Marketwired - November 03, 2016) - Celtaxsys, Inc., a clinical stage drug development company advancing therapies for patients with rare inflammatory diseases, announced today the...
October 28, 2016 08:02 ET | Source: Celtaxsys, Inc.

Celtaxsys Announces Publication of Results Demonstrating the Safety, Tolerability and Optimal PK/PD Profile of First-In-Class Anti-Inflammatory Medicine, Oral Acebilustat, in Phase 1 Clinical Trials Including Cystic Fibrosis Patients

ATLANTA, GA--(Marketwired - October 28, 2016) - Celtaxsys, Inc., a clinical stage drug development company focused on advancing therapies for patients with rare inflammatory diseases, announced today...

Next Page keyboard_arrow_right